Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The study will be an open-label, pilot study in virologically suppressed patients comparing
the efficacy, safety and tolerability of two Antiretroviral regimen strategies:
Arm A: "Immediate switch" Rilpivirine/Emtricitabine/Tenofovir (single tablet formulation
(STF))at randomization
Arm B: "Delayed switch" Continue Nevirapine/Lamivudine/other Nucleoside reverse transcriptase
inhibitor (NRTI)through 24 weeks then switch to STF of Rilpivirine/emtrictabine/tenofovir and
followed through 48 weeks.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Philip Grant
Collaborators:
Gilead Sciences Rwanda Biomedical Center
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Nevirapine Rilpivirine Tenofovir